Pulmonx Corp (LUNG) · Oct 27, 2026 · Earnings

Pulmonx earnings beat as revenue growth returns, China still waits

Beat — Revenue $22.84M vs ~$21.93M consensus; EPS $(0.19) vs ~(0.26) consensus

Pulmonx earnings beat Q3 revenue and EPS expectations, with U.S. growth and lower costs offsetting the unfinished China restart.

Pulmonx is a commercial-stage medical-device company rebuilding adoption of its Zephyr lung valve, with management trying to restart U.S. growth, sharpen its sales organization, and resume China shipments after renewing its registration certificate. Its core products target severe emphysema and COPD patients who remain symptomatic despite medical treatment.

The quarter cleared expectations on both revenue and loss. Revenue reached $22.8 million, up 6% year over year, versus published consensus of roughly $21.93 million; GAAP loss per share was $0.19 versus consensus near $0.26. That is a real beat, not merely a cleaner presentation of an in-line quarter. The EPS comparison is especially favorable because the loss narrowed despite higher interest expense and a larger share count.

MetricQ3 2026Q3 2025 / consensusRead
Revenue$22.835M (Financial Highlights)$21.502M prior year; ~$21.93M consensus+6.2% YoY; above consensus
GAAP EPS$(0.19) (Income Statement)$(0.34) prior year; ~(0.26) consensusBetter than expected
Gross margin76% (Financial Highlights)75% prior yearExpanded 1 point
Operating expenses$24.889M (Income Statement)$30.445M prior yearDown 18%
Adjusted EBITDA$(3.528)M (Adjusted EBITDA reconciliation)$(8.223)M prior yearLoss narrowed materially
Cash and equivalents$52.690M (Balance Sheet)$69.751M at Dec. 31, 2025Liquidity remains pressured

The commercial recovery is becoming visible, but it is not broad-based yet. U.S. revenue grew 7% in the quarter, while international revenue grew 5%; excluding China, international revenue rose 9%. That supports management’s claim that the sales-force and commercial restructuring are beginning to work. But China still produced no revenue in the quarter, so the headline growth is coming from the existing U.S. and non-China international business rather than a full global recovery. 〔0〕

The cost reset is doing more work than the top line. Quarterly operating expenses fell to $24.9 million from $30.4 million, and adjusted EBITDA losses narrowed to $3.5 million from $8.2 million. Management also cut full-year operating-expense guidance to $108 million-$109 million from the prior $109 million-$111 million range, while reducing expected cash burn to approximately $22 million from approximately $23 million. This improves runway, but the company still ended September with $52.7 million of cash and $37.7 million of long-term debt, so the business remains dependent on continued execution rather than self-funded profitability.

The beat is meaningful, but the recovery is still early. Nine-month revenue remains down 2.5% year over year, including a 1.3% decline in the United States; the quarter’s return to growth is therefore a reversal of recent weakness, not yet proof of a sustained acceleration. The market had already been expecting a third-quarter return to growth after management’s second-quarter comments, which makes the upside mainly a matter of execution and magnitude rather than a surprise in direction.

Bottom line: This is a genuine earnings beat that advances Pulmonx’s turnaround story: U.S. growth has resumed, expenses are falling, and China provides potential upside once shipments restart. The result matters, but the company still needs several quarters of growth to prove the reset is durable rather than one good quarter.

What to watch next

China commercial restart and Q4 results

Original filing on SEC EDGAR

Pulmonx earnings beat as revenue growth returns, China still waits | LUNG Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.